Teleoplexis · KNBi, Poznań University of Technology, Poland
Computational drug discovery, from docking to biosimilar similarity
A drug discovery lab in Poznań, Poland. We develop PROTO-NOOS, an open-source pipeline that generates small molecules de novo, docks and co-folds them with the target, simulates intracellular target engagement and ranks the result with a decomposable score. We are also building probe-based pharmacophore mapping of pockets and whole proteins, and similarity methods for biosimilar antibodies.
EcDHFR · PDB 6XG5 · trimethoprim · NADPH EcDHFR · PDB 6XG5 · illustration: probe clusters map the pocket, independent of the bound compound Illustration: human insulin B-chain against a lispro-type analogue
Work
Structure first
Docking · Boltz-2
Docking and co-folding
AutoDock Vina scoring, Boltz-2 co-folding.
PROTO-NOOS
Seven-stage pipeline
REINVENT4 generation to a decomposable score.
EcDHFR campaign
3.8 million generated
In development
Probe-based pharmacophore mapping
Small probes map the pharmacophore of a pocket or a whole protein. The map belongs to the target, not to one compound.
In development
Similarity of biosimilar antibodies to their reference
The sequence is fixed by definition. We predict where a different cell line and process introduce differences in the full antibody, and whether those differences matter functionally.
- ReferenceDossier of the originator product
- Structure3D model, antibody numbering
- AttributesWhich quality attributes are critical
- VariantsGlycans and chemical liabilities from process conditions
- DecisionSimilar or not, against quality ranges
Predictions are checked against measurements on a small panel of samples.
Audit
13findings against our own results.
Open source
Code on GitHub
Research
Three posters
Evidence · EcDHFR campaign
Measured results
Ranking quality by endpoint
Enzymatic n = 1,003, 10-fold GroupKFold. Whole-cell n = 2,116, 67 actives. Full results
Whole-cell endpoint
0.483ROC AUC of score v2. Random ranking: 0.554. Affinity alone: 0.653.
Compute
62%of a 50-molecule run is Boltz-2; dynamics adds about 33%.
Seconds per molecule
Campaign scale
Target engagement

Stage agreement

Dynamics

Library
PROTO-NOOS
Seven stages
01 · REINVENT4
De novo generation
02 · RDKit, gradient boosting
Permeability and efflux
03 · cellTE
Target engagement
04 · Boltz-2
Structure and affinity
05 · GROMACS
Molecular dynamics
06 · COBRApy, iML1515
Systems biology
07 · Desirability functions
Multi-criteria scoring
Overview
All stages in detail
Research
Posters
Orchestrating open-access bioinformatics
Pipeline architecture and an EcDHFR campaign.
Preprint · 13 May 2026Biocomplex analysis: EcDHFR–NADPH–ligand dynamics
Dynamics, metadynamics, MM-GBSA, CP2K.
Manuscript · 8 May 2026Rational compute allocation via mutual information and uncertainty
Uncertainty-aware routing of the expensive stages.
Collaboration
What we need
Compute
GPU time
Boltz-2 and molecular dynamics are about 95% of a run.
Validation
Wet lab
Synthesis, enzymatic and whole-cell assays.
Review
Expert eyes
Dynamics, flux balance and experimental design.
Partnerships
Collaborate with us
Join
